600PTREATMENT (T) OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) ≥75 YEARS (Y) OLD IN CLINICAL PRACTICE: A MULTICENTER ANALYSIS

ABSTRACT Aim: CRC pts have a median age of incidence > 65y although they are largely under-represented in phase III trials. This large population contains pts unfit for T, those suitable for monotherapy or for doublets and the impact of chemotherapy (CHT) outside clinical trial is unclear. Aim of the study was to retrospectively analyse T of elderly mCRC pts. Methods: Kaplan-Meir method was used for OS, the log-rank or Tarone-Ware test for diferences between subgroups, Cox's proportional hazard model to assess the impact of known prognostic factors and T. Results: 751 pts with mCRC observed from January 2000 to January 2013 were collected. Median age was 79y (75-93); Variables HR (CI95%) P value Sex 1.21 (1.01-1.46) 0.04 Age 1.75 (1.45-2.12) ECOG PS 2.51 (1.94-3.25) CT 2.14 (1.68-2.73) S of metastasis 2.48 (1.88-3.29) S of primary tumor 1.66 (1.31-2.11) Site of metastasis 1.33 (1.09-1.63) 0.006 Conclusions: These data show that in clinical practice treatment of metastatic disease has a positive effect on elderly pts OS, confirmed at multivariate analysis. KRAS analysis deserve further evaluation. Update results will be presented. Disclosure: All authors have declared no conflicts of interest.